CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia.
SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
急性淋巴细胞白血病（ALL）的治疗格局正在迅速演变，新疗法不断挑战传统治疗范式。尽管异基因造血细胞移植（allo-HCT）对许多高危患者仍不可或缺，但可测量残留病（MRD）监测的进展以及免疫治疗在更早期治疗线中的日益广泛应用，已重塑了移植决策。供者可及性、预处理策略和移植后护理的改善扩大了移植的可及性并提高了生存率，但复发和毒性仍是主要挑战。本综述探讨了allo-HCT在ALL中不断演变的作用，重点介绍了关键进展和持续存在的挑战。
The landscape of acute lymphoblastic leukemia (ALL) treatment is rapidly evolving, with new therapies challenging traditional treatment paradigms. While allogeneic hematopoietic cell transplantation (allo-HCT) remains essential for many high-risk patients, advances in measurable residual disease (MRD) monitoring and the increasing use of immunotherapies in earlier treatment lines have reshaped transplant decision-making.
Improvements in donor availability, conditioning strategies, and post-transplant care have expanded access and improved survival, yet relapse and toxicity remain major challenges. This review examines the evolving role of allo-HCT in ALL, highlighting key advancements and ongoing challenges.
MEMBER ACCOUNT
登录成功会直接打开下一页。
